Search

Anti-CCR5 Agents Block Cancer Metastasis, CytoDyn

The EPO published patent application EP3947431A1 filed by CytoDyn Inc. on April 15, 2026, titled Anti-CCR5 Agents and Methods of Treatment That Block Cancer Metastasis or Enhance Cell Death Induced by DNA Damaging Chemotherapy. The application lists inventors Richard G. Pestell and Scott Kelly and covers anti-CCR5 agents for blocking cancer metastasis or enhancing cell death from DNA-damaging chemotherapy. The designation covers 35 European Patent Convention member states, potentially providing CytoDyn with patent protection across those jurisdictions upon grant.